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Introduction 
Cancer is not a solo performance, but rather an ensemble pro­
duction.Tumor cells play the leading villains, with a diverse sup­
porting cast of normal cells that can be recruited to aid their 
malignant progression. The supporting players in the tumor 
microenvironment include stromal fibroblasts, infiltrating 
immune cells, the blood and lymphatic vascular networks, and 
the extracellular matrix (Figure 1). Normal cells can contribute 
both positive and negative signals to the tumor. They can be co­
opted or modified by the cancer cells to produce a variety of 
growth factors, chemokines, and matrix-degrading enzymes 
that enhance the proliferation and invasion of the tumor. In addi­
tion, these conscripted normal cells may provide a support sys­
tem for tumor cells to fall back on following traditional cytotoxic 
therapies. Furthermore, environmental conditions within the 
tumor, caused by changes in the stroma, such as increased 
interstitial fluid pressure and changes in vascular flow, reduce 
the effective delivery of anticancer drugs. Multitargeted 
approaches, in which tumor cells and co-opted cells in the 
microenvironment are simultaneously inhibited, may offer a 
more efficient way to treat cancer by circumventing these prob­
lems. One advantage of therapies targeting the microenviron­
ment is that these nontumor cells are presumably genetically 
stable, which is in contrast to tumor cells that are known to be 
genetically unstable and thus can accumulate adaptive muta­
tions and rapidly acquire drug resistance. However, a limitation 
of perturbing the cells in the tumor microenvironment is that a 
delicate balance exists between their tumor-inhibitory and 
tumor-promoting functions. As such, we need to identify and tar­
get the key molecular differences between these cells under 
normal tissue homeostasis versus when they have been co­
opted or altered by the tumor microenvironment. Recent experi­
ments have suggested various approaches to target different 
cell types in the tumor microenvironment, and will be the 
emphasis of this review. 
The tumor stroma: An active player in cancer 
All tissues require an extracellular network to provide structural 
support and facilitate the continuous cell-cell communication 
that maintains tissue homeostasis. An important regulator of 
normal tissue behavior is the extracellular matrix (ECM), which 
surrounds cells and is composed of many types of macromole-
Figure 1. Therapeutic strategies that have been designed or suggested to target different cells in the tumor microenvironment 
These strategies include targeting the tumor cells themselves, with traditional therapies such as chemotherapy and radiotherapy (which will also kill normal 
cells) and targeted vaccines, or molecular approaches to inhibit oncogenes such as Ras, EGFR, and Her2. Among the targets to inhibit in normal cells are 
members of the VEGF/VEGFR family (vascular or lymphatic endothelial cells), PDGF/PDGFR family (pericytes and potentially fibroblasts and lymphatics), 
matrix-degrading enzymes (made by inflammatory cells in large part, with BM/ECM components as substrates), and inhibitors of chronic inflammation. 
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Table 1. Drugs targeting the tumor microenvironment 
Name Cellular target Mechanism of action	 Status 
Avastin Endothelial cells Humanized monoclonal antibody against VEGF-A FDA-approved 
(Bevacizumab) (ECs) 
Neovastat (AE941) ECs Natural antiangiogenic compound isolated from shark cartilage that inhibits VEGF signaling Phase III 
and MMP activity and specifically induces EC apoptosis 
PTK787 (vatalanib) ECs Small molecule receptor tyrosine kinase (RTK) inhibitor, inhibits VEGF-R2, but also VEGFR-1, Phase II/III 
VEGFR-3, PDGFR-β 
Interferon-alpha ECs Inhibits angiogenesis in part by downregulating bFGF expression Phase II/III 
Combretastatin A4 ECs Specifically interferes with endothelial microtubule assembly, resulting in rapid vascular Phase II 
dysfunction in tumors 
LY317615 ECs Inhibitor of protein kinase Cβ Phase II 
Atrasentan ECs Small molecule selective inhibitor of endothelin A receptor Phase II 
ZD6474 ECs Small molecule RTK inhibitor, inhibits VEGF-R2 and EGFR, and to a lesser extent Phase I/II 
VEGFR-1 and R-3 
VEGF-Trap ECs Soluble VEGF receptor: composite fusion protein of VEGFR-1 and VEGFR-2 with Phase I/II 
Fc fragment of IgG 
2-ME ECs 2-Methoxyestradiol (2-ME) is a small molecule inhibitor that blocks angiogenesis Phase I 
in part by HIF-1α downregulation 
Thalidomide ECs, Glutamic acid derivative that inhibits angiogenesis, in part by inhibition of NF-κB, TNF-α, Phase III 
other cell types IL-6, and VEGF; also increases apoptosis and stimulates immune response 
CC-5013 ECs, Synthetic analog of thalidomide, with more potent inhibition and less toxic side effects Phase II/III 
other cell types 
Gleevec (imatinib) Pericytes, stromal RTK inhibitor: in addition to inhibiting Bcr-Abl kinase, also inhibits PDGF-R and c-Kit kinases FDA-approved 
fibroblasts 
SU11248 Pericytes, ECs Small molecule RTK inhibitor, inhibits VEGF-R family members (VEGFR-1, -2, -3), Phase II 
PDGFR-β, and CSF-1R 
Vitaxin ECM Humanized monoclonal anti-αvβ3 antibody Phase II 
Volociximab ECM Humanized monoclonal anti-α5β1 antibody Phase II 
Cilengitide ECM Cyclic peptide inhibitor of αvβ3 and αvβ5 Phase I/II 
(EMD121974) 
Suramin	 Inhibits ECM Polysulfonated napthylurea; inhibits matrix remodeling and blocks FGF, PDGF, IGF-1, TGF-α, Phase I/II 
turnover and TGF-β function 
Sibrotuzumab	 Carcinoma- Humanized monoclonal antibody against fibroblast activation protein Phase I 
associated 
fibroblasts 
PI-88	 Inflammatory Heparan sulfate mimetic; inhibits heparanase activity and function of heparin-binding Phase I/II 
cells, ECs growth factors 
Table listing agents that target different cells in the tumor microenvironment that are currently in clinical trials for cancer or have been approved by the 
FDA. Abbreviations: EC, endothelial cell; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; VEGFR, vascular endothelial 
growth factor receptor; PDGFR, platelet-derived growth factor receptor; EGFR, epidermal growth factor receptor; HIF-1, hypoxia-inducible factor; NF-κB, 
nuclear factor of κB; TNF, tumor necrosis factor; IL-6, interleukin 6; CSF-1R, colony-stimulating factor receptor; ECM, extracellular matrix; IGF, insulin-like 
growth factor; TGF, transforming growth factor. See Supplemental Data at http://www.cancercell.org/cgi/content/full/7/6/513/DC1/ for table and 
references in full. 
cules, including collagen, laminin, fibronectin, and heparan sul­
fate proteoglycans (HSPGs). These proteins are linked in an 
intricate, three-dimensional matrix (Kalluri, 2003). One special­
ized ECM, the basement membrane (BM), separates the 
epithelium from the stroma, and underlies endothelial cells, per­
icytes, and other cell types. Maintaining organ homeostasis can 
prevent neoplastic transformation in normal tissues by ensuring 
firm cell-cell contacts, mediated by tight-junction proteins and 
cell adhesion molecules, such as β1 integrins and E-cadherin 
(Weaver et al., 1997;Wrobel et al., 2004; reviewed in Bissell and 
Radisky, 2001). In tumors, these protective constraints can be 
overridden by remodeling of the BM/ECM. 
BM/ECM remodeling is mediated in an orchestrated man­
ner by several families of matrix-degrading enzymes, including 
proteases of the cysteine, serine, and matrix metalloprotease 
(MMP) classes, as well as endoglycosidases such as 
heparanase (reviewed in Carmeliet, 2003; Vlodavsky et al., 
2002). Controlled BM/ECM degradation is necessary for angio­
genesis and invasion of tumor cells, into both the surrounding 
normal tissue and the blood and lymphatic systems. The 
BM/ECM is also a rich source of sequestered heparin binding 
progrowth and proangiogenic factors, which are made available 
following increased production of matrix-degrading enzymes 
(reviewed in Pupa et al., 2002). In many cancers, matrix­
degrading enzymes are provided by infiltrating innate immune 
cells (Coussens et al., 2000; Coussens and Werb, 2002; 
Pollard, 2004), and the inhibition of certain enzymes, such as 
cysteine cathepsins and heparanase, offers the potential to 
block multiple nodes in the tumor microenvironment (Joyce et 
al., 2004; Joyce et al., 2005) (Table 1). 
However, caution should be exercised in considering broad­
spectrum inhibitors of matrix-degrading enzymes for clinical 
use, as ECM degradation is a delicate balance. Some matrix­
degrading enzymes such as MMPs can also release antiangio-
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genic proteins such as endostatin, angiostatin, and tumstatin 
(Hamano et al., 2003; Kalluri, 2003), which inhibit tumorigene­
sis. This inhibitory role of certain MMPs may explain, at least in 
part, the failure of the broad-spectrum MMP inhibitors (MMP-I) 
in the clinic. This example highlights the importance of certain 
criteria in considering antistromal therapies, which include the 
appropriate patient selection, the requisite demonstration that 
drugs specifically inhibit their target in these patients, and the 
selection of the appropriate endpoints for what is likely to be 
cytostatic rather than cytotoxic therapy (see Coussens et al., 
2002 for a discussion of the MMP inhibitor trials). 
Additional therapeutic targets in the extracellular milieu 
include the integrins, a family of heterodimeric receptors that 
connect cells to ECM proteins and transduce intracellular sig­
nals. Several integrins, including αvβ3, αvβ5, α5β1, and α6β4, 
are upregulated in cancer, and are expressed on endothelial 
cells, tumor cells, or both (Guo and Giancotti, 2004; Hood and 
Cheresh, 2002). Based on the known functions of these inte­
grins, blocking these proteins would be expected to interfere with 
cell survival, angiogenesis, cell adhesion, and motility, thus 
impacting tumor viability. Indeed, disruption of individual inte­
grins using antibodies or small molecule inhibitors produced 
encouraging results in animal models, and some of these drugs 
are now in clinical trials (reviewed in Jin and Varner, 2004) (Table 
1). However, contradicting results have been observed between 
pharmacologic versus genetic ablation of αv integrins, with αv 
knockout mice showing enhanced pathological angiogenesis, 
whereas antiangiogenic results were obtained with the inhibitors 
(reviewed in Hynes, 2002).Thus, it will be of particular interest to 
see how the αvβ5 and αvβ3 antagonists perform in the ongoing 
phase II trials (Table 1). Another compelling reason to target inte­
grins is that some of them have been shown to be involved in cell 
adhesion-mediated drug resistance (CAM-DR), which has been 
observed in a variety of cancer cell types, including small cell 
lung cancer, myeloma, and glioma cells, among others 
(Damiano et al., 1999; Sethi et al., 1999; reviewed in Shain and 
Dalton, 2001). β1-integrin blocking antibodies have been shown 
to abrogate CAM-DR (Sethi et al., 1999).Thus, ECM remodeling 
during tumorigenesis could contribute to CAM-DR by both alter­
ing the integrin repertoire and affecting the local ECM composi­
tion (Morin, 2003). Based on current results, β1 integrin appears 
to be a promising therapeutic target. 
Fibroblasts are another essential component of the tissue 
stroma, and play an important role in preventing the progression 
of transformed epithelial cells. This has been demonstrated by 
coculture experiments in which normal fibroblasts prevented 
transformation of initiated prostatic epithelial cells (Olumi et al., 
1999), and could even promote the reversion of neoplastic 
epithelial cells (Hayashi and Cunha, 1991). Recent elegant 
genetic experiments in mice suggest that transforming growth 
factor β (TGF-β) is one of the fibroblast-supplied factors 
involved in suppression of epithelial transformation, in part by 
controlling c-Myc and c-Met signaling in the adjacent tumor 
cells via a paracrine mechanism involving hepatocyte growth 
factor (HGF) (Bhowmick et al., 2004a). Simply rendering fibrob­
lasts unresponsive to TGF-β by genetic inactivation of the TGF­
βRII receptor resulted in transformation of the otherwise 
genetically normal epithelial cells in the prostate and forestom­
ach, a striking demonstration of the powerful influence of stro­
mal fibroblasts on adjacent epithelial transformation. 
Conversely, many studies have shown that fibroblasts resi­
dent in established tumors differ considerably from those in nor­
mal tissues, and are “activated,” highly proliferative, and display 
typical markers of smooth muscle differentiation (Bhowmick et 
al., 2004b). These cells are termed myofibroblasts or carcino­
ma-associated fibroblasts (CAFs), and have been shown to 
enhance malignant epithelial transformation (Hayward et al., 
2001; Olumi et al., 1999; Orimo et al., 2005; reviewed in 
Bhowmick et al., 2004b). Thus, stromal fibroblasts can have a 
bipolar role in cancer, depending on their differentiation state 
and the stage of tumor development. Molecules enriched in acti­
vated fibroblasts, such as the fibroblast activation protein (FAP) 
(Garin-Chesa et al., 1990; Park et al., 1999), CXCL12/ stromal 
derived factor-1 (Allinen et al., 2004; Orimo et al., 2005), HGF 
(Bhowmick et al., 2004a), and cathepsin K (Allinen et al., 2004), 
could provide promising selective targets in the tumor stroma, 
with encouraging evidence to date in preclinical models and a 
phase I clinical trial for an anti-FAP antibody, sibrotuzumab 
(Cheng et al., 2002; Scott et al., 2003) (Table 1). 
Targeting the tumor vasculature: Endothelial cells, 
pericytes, and endothelial progenitor cells 
It is now well established that in order for a tumor to grow 
beyond a certain size, it needs to recruit its own blood supply to 
deliver oxygen and nutrients (Hanahan and Folkman, 1996). 
This size limitation is governed by the diffusion limit for oxygen 
from the nearest blood vessel, which is approximately 100–200 
µm (Folkman et al., 2000). The tumor vasculature is derived by 
angiogenesis, new blood vessel growth from pre-existing ves­
sels, and vasculogenesis, the recruitment of circulating 
endothelial progenitor cells (Carmeliet, 2003; Rafii et al., 2002). 
The concept of angiogenesis as a target for cancer therapy, ini­
tially proposed by Folkman (Folkman, 1971), was met with 
skepticism for decades, but is now widely accepted and being 
applied to the armament of cancer therapeutics. A plethora of 
antiangiogenic agents inhibiting either angiogenic growth fac­
tors or their receptors have been developed (see Table 1 for 
examples) and tested in preclinical experiments (Papetti and 
Herman, 2002). 
Recently, tumor vascular targeting has been expanded to 
include pericytes, which provide both survival signals and struc­
tural support to endothelial cells, contributing to a mature, func­
tional vasculature. The process of vascular maturation involves 
interactions between endothelial cells and pericytes, employing 
several growth factor signaling pathways; and PDGF-B/PDGFRβ, 
VEGF-A/VEGFR2, TGF-β1, and the Angiopoietin/Tie-2 system 
(Carmeliet, 2003).When pericytes are not present, or cannot pro­
duce VEGF in mouse models, the endothelium is now vulnerable 
to VEGF blockade (Benjamin et al., 1999). One way to reduce 
pericyte coverage is to block the signaling pathways involved in 
recruiting pericytes to endothelial cells. PDGFR inhibitors offer a 
means to do this and have been tested as single agents, but with 
limited efficacy (reviewed in Pietras et al., 2003). However, combi­
nations of PDGFR antagonists with a VEGFR2 inhibitor have 
been shown to greatly perburb pericyte-endothelial cell interac­
tions and resulted in tumor regression in a mouse cancer model 
(Bergers et al., 2003). It is important to note that the pericyte­
endothelial connections in the normal tissues examined did not 
appear to be affected by this treatment (Bergers et al., 2003), 
suggesting there are differences between these cell types in 
tumors and normal tissues which can be therapeutically exploit­
ed. Modifications of this therapy have proven even more effective. 
For example, when an adapted chemotherapeutic regimen is 
added, in which tumors are first “debulked” using high-dose 
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chemotherapy, and then treated with continuous low-dose 
(metronomic) chemotherapy in combination with RTK inhibitors 
(Pietras and Hanahan, 2005), tumor regression and survival are 
markedly improved. 
Another way to potentially block a tumor’s blood supply is to 
prevent endothelial progenitor cells (EPCs) from either homing 
to the tumor site or eliciting their vasculogenic program once 
there. There is considerable controversy as to the exact contri­
bution of EPCs to tumor endothelium, with estimates varying 
from 0 to >90% in mouse cancer models (De Palma et al., 2003; 
Li et al., 2004: Lyden et al., 2001; Rafii et al., 2002; Rajantie et 
al., 2004), contrasting with a <5% median contribution in the 
human cancers that have been analyzed (Hilbe et al., 2004; 
Peters et al., 2005; Yu et al., 2004). While simultaneous inhibi­
tion of VEGFR1 and VEGFR2 resulted in tumor regression in 
mouse xenograft models, and was suggested to be a conse­
quence of a reduction in the recruitment of EPCs (Lyden et al., 
2001; Rafii et al., 2002), it remains to be seen whether EPC 
reduction will ever be a viable antiangiogenic option in the clinic. 
However, the quantitation of EPCs or viable circulating endothe­
lial cells (CEC) in the peripheral blood may at least offer a 
potential surrogate marker for monitoring the correct adminis­
tration and subsequent efficacy of antiangiogenic therapies 
(Shaked et al., 2005; Willett et al., 2004; reviewed in Kerbel and 
Folkman, 2002). 
Given the various successes of antiangiogenic drugs in 
mouse cancer models, it was somewhat surprising that the ini­
tial results of these agents tested singly in the clinic were not 
particularly encouraging (reviewed in Garber, 2002). One possi­
ble explanation for the discrepancy between preclinical and clin­
ical results is that subcutaneous xenograft models are often 
used in preclinical testing of anticancer agents, including 
antiangiogenic drugs. The particular concern with using these 
models to test antistromal therapies is that the tumor microenvi­
ronment of cancer cells growing subcutaneously in a nude 
mouse may be very different from the microenvironment of 
endogenous tumors. This may result in substantial molecular 
changes, such as differences in the profile of vascular-specific 
proteins (Joyce et al., 2003). In this regard, orthotopic trans­
plantation models or genetically engineered mice (GEM) may 
more accurately recapitulate the tumor microenvironment of 
each organ-specific cancer. 
More recent data from the clinical trials of the VEGF-specif­
ic antibody, bevacizumab (Avastin) (Table 1), showed that in 
patients with metastatic colorectal cancer, there was a signifi­
cant survival benefit when combined with chemotherapy 
(Ferrara et al., 2004; Hurwitz et al., 2004), leading to the FDA 
approval of bevacizumab and renewing confidence in antiangio­
genic therapies. Recently reported interim analyses from phase 
III trials in non-small cell lung cancer and metastatic breast can­
cer show similar survival improvements when Avastin is com­
bined with standard chemotherapy, as the first-line therapy (see 
http://cancer.gov/newscenter/pressreleases/AvastinBreast and 
http://www.gene.com/gene/news/press-releases/display.do? 
method=detail&id=8207). This suggests that combinatorial 
approaches targeting both tumor cells and supporting cells will 
likely prove most effective in treating human cancers. 
Intriguingly, VEGF receptors have been shown to be expressed 
in some human cancers, including colon cancer (Ryden et al., 
2003; Fan et al., 2005), thus raising the possibility that anti-
VEGF therapies may simultaneously target endothelial and 
tumor cells in this subset of cancers. 
Improving drug delivery to the tumor 
The success of many anticancer therapies, whether they target 
the tumor or host cells, depends upon effective drug delivery. 
One of the reasons that many chemotherapeutic regimens may 
ultimately fail is that in addition to the development of multidrug 
resistance, microenvironmental influences, such as the previ­
ously mentioned CAM-DR, and increases in interstitial fluid 
pressure (IFP) can affect the bioavailability and efficacy of anti­
cancer agents (reviewed in Morin, 2003). In order for an anti­
cancer agent to be therapeutically effective, it should be 
uniformly distributed throughout the tumor circulation, cross the 
vessel wall, and pass through the extracellular matrix. Tumors 
create multiple obstacles to drug transport, and as the microen­
vironment can be heterogenous within a tumor, the require­
ments for effective drug delivery may vary considerably. One of 
these barriers is an increase in IFP within tumors (particularly at 
the tumor core) that is significantly higher than in normal tissues 
(reviewed in Heldin et al., 2004). Elevated IFP is caused in part 
by changes in ECM composition, fibroblast-mediated contrac­
tion of the interstitial space, and a nonoperational lymphatic 
system within the tumor. Another barrier results from the chaot­
ic nature of the tumor vasculature, as tumor vessels are dilated, 
leaky, and tortuous (Carmeliet and Jain, 2000), which further 
contributes to decreased drug delivery. 
Strategies to overcome these environmental barriers, by 
reducing IFP or “normalizing” the vasculature for example, have 
been championed by Jain, Heldin, and others (Heldin et al., 
2004; Jain, 2001; Jain, 2005). In fact, these two phenomena are 
closely linked: vessel normalization, in which inefficient and 
immature blood vessels are selectively eliminated, results in 
decreased IFP and increased uptake of drugs in the tumor. The 
administration of VEGFR2-blocking antibodies, PDGF antago­
nists, and TGFβ inhibitors, among others, effectively reduces 
IFP, resulting in enhanced drug uptake (Lammerts et al., 2002; 
Pietras et al., 2002; Tong et al., 2004), as exemplified by the 
combinatorial efficacy of chemotherapy and PDGF inhibitors in 
reducing tumor growth in preclinical models (Pietras et al., 
2002). An exciting recent development has been the demon­
stration in the clinic that even a single dose of the VEGF-specif­
ic antibody, bevacizumab, results in vascular normalization and 
decreased IFP (Willett et al., 2004). However, getting the timing 
right will be crucial with these agents. The prediction is that nor­
malization of the tumor vasculature would result in a temporary 
increase in drug and oxygen uptake, before the tumor vessels 
(and thus the delivery system) are ultimately destroyed. In this 
regard, establishing the correct treatment “window” for each 
inhibitor, or for drugs in combination, will be essential.The proof 
of this concept was elegantly demonstrated using VEGFR2 
blockade followed by radiation therapy in an orthotopic glioma 
model. The effects of radiation synergized with the antiangio­
genic, normalization therapy, but only in a very narrow treatment 
window (Winkler et al., 2004). 
Inflammation and cancer 
The association between chronic inflammation and cancer has 
been noted by epidemiologists for many years, and has recent­
ly come to the fore of cancer research, as evidence accumu­
lates of the causal link between the two. Among the human 
cancers associated with chronic inflammation are colorectal, 
gastric, bladder, liver, lung, pancreatic, and cervical cancers, in 
which the inflammatory stimulus can range from chronic pan­
creatitis to Heliobacter pylori infection (Balkwill et al., 2005; 
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Coussens and Werb, 2002). While infiltrates of adaptive 
immune cells, particularly CD4+ and CD8+ T cells, in tumors 
are typically associated with a more favorable prognosis, in can­
cers associated with chronic inflammation, the infiltrating cells 
are of the innate immune class, and invariably correlate with a 
poor prognosis (Pollard, 2004; Vakkila and Lotze, 2004). The 
innate immune infiltrate predominantly consists of cells of the 
myeloid lineage (macrophages, granulocytes, mast cells, neu­
trophils, etc.), which produce chemokines, angiogenic growth 
factors, and matrix-degrading enzymes, contributing to a rich 
environment for tumor growth and invasion (Coussens and 
Werb, 2002; Pollard, 2004). This class of inflammatory cells can 
also enhance the genomic instability of the tumor through the 
production of reactive oxygen and nitrogen species, which can 
form peroxynitrate, a DNA-damaging agent (Maeda and Akaike, 
1998; reviewed in Hussain et al., 2003). 
These observations would suggest that reducing chronic 
inflammation would lower the risk of developing cancer, and 
indeed epidemiological studies have demonstrated that people 
taking nonsteroidal anti-inflammatory drugs (NSAIDs) have a 
clear reduction in their risk of developing colorectal cancer 
(Thun et al., 1991), and possibly other tumors. As a result, there 
were high expectations for the next-generation NSAIDs, the 
selective COX-2 inhibitors, in the prevention and treatment of 
cancers associated with chronic inflammation. However, the 
current controversy surrounding the association of long-term 
high-dose COX-2 inhibitor use with an elevated risk of cardio­
vascular events (Bresalier et al., 2005) indicates that alternative 
drugs or molecular targets will need to be identified. Additional 
proinflammatory factors that are potential targets for cancer 
prevention and treatment include IκB kinase (IKK), the 
upstream kinase that activates NF-κB (Karin et al., 2004; Lam 
et al., 2005), TNF-α (Palladino et al., 2003), interleukins IL-1, IL­
6, and IL-8, and certain chemokines and their receptors 
(Balkwill, 2004), inhibitors of many of which are currently being 
tested in clinical trials for inflammatory conditions. 
An alternative strategy could be to specifically target the 
protumorigenic factors supplied by innate immune cells during 
chronic inflammation, rather than systemic inhibition of the 
inflammatory response per se. Of course, this requires identify­
ing the proteins that are either selectively expressed or highly 
upregulated in tumor-infiltrating immune cells. Tumor-infiltrating 
immune cells undergo a processive maturation or “education” 
within the tumor microenvironment (reviewed by Pollard, 2004), 
resulting in molecular and phenotypic changes that could be 
exploited therapeutically. Some molecules that are upregulated, 
though not exclusively expressed by these cells, include uroki­
nase plasminogen activator receptor (uPAR) (Hildenbrand et 
al., 1999), CSF-1 (Lin et al., 2001), MMP-9 (Coussens et al., 
2000; Giraudo et al., 2004), cathepsins (Joyce et al., 2004), and 
heparanase (Joyce et al., 2005); pharmacologic or genetic abla­
tion of these molecules has been shown to significantly perturb 
tumor progression in animal models. Future identification of 
genes that are truly specific to tumor-infiltrating innate immune 
cells and functionally contribute to tumorigenesis should further 
enhance the antitumor selectivity of this approach. 
Finally, in addition to switching innate immune cells toward 
a protumorigenic function, changes in the tumor microenviron­
ment can actively contribute to immune tolerance, preventing 
rejection of the tumor by the immune system. One way this can 
occur is by changes in the balance of cytokines (increased 
VEGF, TGFβ, IL-10, IL-6, COX-2, etc., and reduced IL-4, IL-12, 
IFN-α, IFN-γ, and GM-CSF) within the tumor, which actively 
suppresses dendritic cell (DC) maturation. This significantly 
dampens the antigen presenting function of DCs, which then 
contributes to immune tolerance (recently reviewed in Zou, 
2005). Various strategies have been adopted to break immune 
tolerance, including systemic administration of effector 
cytokines that enhance the immune response (e.g., IL-2, IL-12, 
IFN-γ). While there is a therapeutic benefit from these treat­
ments in some patients with melanoma, renal cell carcinoma, 
and prostate cancer, there are significant side effects associat­
ed with prolonged use (see Dranoff, 2004 for review). Thus, 
cytokine administration directly into the tumor (Forni et al., 
1988) or strategies to restore the cytokine imbalance in a more 
localized manner may be more effective and less toxic. 
The metastatic microenvironment 
In any discussion of the tumor microenvironment, we should 
also consider the environmental conditions in which metastatic 
tumors develop. Metastatic cells need an appropriate microenvi­
ronment in which they can survive and proliferate (Fidler, 2003). 
While experimental systems have shown that tumor cells arrive 
at secondary sites at relatively high rates, they only thrive in cer­
tain, stereotypical sites (Chambers et al., 2002). For example, 
prostate cancer cells predominantly metastasize to bone, 
whereas colorectal cancer cells preferentially metastasize to 
the liver. This suggests that tumor cells from a given tissue of 
origin may be more prone than others to possess the capabili­
ties that are necessary to invade and prosper in a particular dis­
tant organ. Thus, defining the molecular microenvironment in 
the organs to which tumor cells successfully metastasize is of 
vital importance in selecting targets for interfering with either the 
homing or the survival of metastatic cells. 
An important advance in this direction came from the gene 
expression analysis of chemokines and their receptors in breast 
cancer (Muller et al., 2001). The authors found that two 
chemokine receptors (CXCR4 and CCR7) were highly 
expressed on metastatic breast cancer cells. Their respective 
ligands (CXCL12 and CCL21) were preferentially expressed in 
the lung and regional lymph nodes, two sites that breast cancer 
frequently metastasizes to. When the interaction between one 
of these pairs (CXCL12/CXCR4) was blocked in vivo using neu­
tralizing antibodies, there was a significant reduction in breast 
cancer metastases to both the lung and lymph nodes (Muller et 
al., 2001). Identification of similar chemokine ligand-receptor 
pairs for other primary cancers and the organs to which they 
preferentially metastasize (reviewed in Zlotnik, 2004) could be a 
promising avenue for neutralization strategies. 
Inhibitors of chemokines and their receptors are in preclini­
cal development (reviewed in Balkwill, 2004), and offer one 
means to interfere with the homing of tumor cells to secondary 
organs. Another therapeutic strategy is to block the dissemina­
tion of tumor cells at the source, by inhibiting the development 
of blood and lymphatic circulatory systems within the tumor. 
Angiogenesis inhibitors are expected to block metastatic spread 
and growth.This hypothesis is supported by recent experiments 
in which potent VEGF inhibition (using the VEGF-Trap, Table 1) 
in a breast xenograft model with established lung metastases 
resulted in regression of both the primary and secondary 
tumors (Huang et al., 2003). Similarly, interfering with tumor 
lymphangiogenesis using a soluble VEGFR3 inhibitor (He et al., 
2002) or a VEGF-C antibody (Stacker et al., 2001) resulted in 
decreased lymph node metastases (see Achen et al., 2005 for 
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review). Recent findings have implicated PDGF-BB and its 
receptors in tumor lymphangiogenesis (Cao et al., 2004), thus 
suggesting additional therapeutic applications for PDGFR 
inhibitors (Table 1). 
Challenges and perspectives 
Whereas cancer cells employ an enormous variety of genetic 
changes to elicit tumorigenesis, changes in the cancer microen­
vironment may be common to many tumor types, raising the 
hope that therapeutic targeting of these events could be gener­
ally applicable. Identifying the most important molecular players 
in the microenvironment of each tumor type is the first step 
toward this goal. Expression and proteomic profiling of the indi­
vidual cell types constituting the cancer microenvironment 
(Allinen et al., 2004; Oh et al., 2004; St Croix et al., 2000) repre­
sent important advances. Determining how the molecular profile 
of the microenvironment changes as tumors progress will be 
critical for identifying targets to select “normal” cells in the tumor 
microenvironment that have been altered during tumor progres­
sion. Recent studies of endothelial cells (Benezra et al., 2001; 
Hoffman et al., 2003; Joyce et al., 2003) and stromal fibroblasts 
(Park et al., 1999; Bhowmick et al., 2004a, 2004b) have identi­
fied molecular differences between nontumor cells in the 
microenvironment of preneoplastic lesions compared to tumors. 
These proteins themselves could be therapeutically targeted or 
used as “zip codes” to specifically deliver cytotoxic agents to 
these converted “normal” cells. Thus, if we can truly selectively 
target only the cells have been modified by the tumor microenvi­
ronment, it should allow their unmodified precursors in normal 
tissues to remain untouched. Another fundamental question to 
answer will be how much the cancer microenvironment varies 
from one tumor type to another. While the individual molecules 
may vary from organ to organ, there should be common lessons 
that we can learn about the fundamental mechanisms used by 
tumor cells to co-opt normal cells. 
A potential benefit of many of the targets that have been dis­
cussed in this review is that they are implicated in more than 
one pathway or cell type in the tumor microenvironment (Figure 
1). Thus, targeting certain chemokines and their receptors may 
reduce chronic inflammation in the primary tumor, while simul­
taneously preventing the development of secondary tumors. 
Similarly, blocking PDGF and its receptors could interfere with 
both tumor angiogenesis and tumor lymphangiogenesis. The 
challenge now is to specifically inhibit the protumorigenic roles 
of these normal cells in cancer, while maintaining their homeo­
static functions in normal tissues. 
The good news is that we have a vastly improved set of 
tools to meet this challenge. Both organotypic 3D culture sys­
tems, as pioneered by Bissell and adopted by Brugge and oth­
ers (Muthuswamy et al., 2001; Petersen et al., 1992; 
Schmeichel and Bissell, 2003), and the recent development of a 
“humanized” mammary gland xenograft model (Kuperwasser et 
al., 2004), allow human epithelial cells and stromal cells to be 
studied in vitro and in vivo, and are important advances in iden­
tifying molecular changes mediated by tumor-host interactions. 
Along with tissue-specific genetic knockouts, siRNA-mediated 
knockdown, and selective inhibitors to ablate the key players, 
these approaches ought to facilitate advances in our under­
standing of the tumor microenvironment in the next few years, 
which should translate into improved therapies in the clinic. The 
recent success of antiangiogenic therapy should continue to 
serve as an example for all agents targeting the tumor microen­
vironment. Rational approaches in which cytotoxic agents are 
administered with cytostatic antistromal agents hold consider­
able promise. For example, we could envisage a three-step 
combinatorial approach in which the tumor microenvironment is 
first normalized by antiangiogenic or antistromal therapy, fol­
lowed by treatment with cytotoxic therapies to shrink or even 
eradicate the tumor, then a maintenance regimen, such as low­
dose chemotherapy or other antistromal drugs, could be admin­
istered to keep any remaining cancer cells in check. In 
conclusion, an important step in this direction is the recognition 
that to effectively eliminate renegade cancer cells, we should 
also consider targeting the cast of normal cells that have been 
co-opted into supporting them. 
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